- Eukaryotic expression systems, such as mammalian, yeast, and insect cells, are increasingly vital components in modern biopharmaceutical manufacturing due to their ability to perform complex post-translational modifications and produce human-compatible therapeutic proteins, vaccines, and monoclonal antibodies
- The escalating demand for high-quality biologics, rising prevalence of chronic diseases, and growing investments in gene and cell therapy development are key drivers fueling the adoption of eukaryotic expression systems across pharmaceutical and biotechnology industries
- North America dominated the eukaryotic expression systems market with the largest revenue share of 41.6% in 2024, driven by the strong presence of key biologics manufacturers, advanced healthcare infrastructure, high R&D spending, and favorable regulatory support. The U.S. leads the region with extensive biopharma production capabilities and adoption of advanced expression platforms
- Asia-Pacific is expected to be the fastest-growing region in the eukaryotic expression systems market, projected to register a CAGR of 11.8% from 2025 to 2032, fueled by rapid expansion of the biotechnology sector, growing outsourcing trends, and rising healthcare investments in countries such as China, India, and South Korea
- CHO (Chinese Hamster Ovary) cell line systems dominated the eukaryotic expression systems market with a market share of 34.6% in 2024, owing to their extensive use in producing therapeutic proteins, especially monoclonal antibodies, due to their high expression efficiency, scalability, and capacity for proper protein folding and post-translational modifications essential for biologic function and safety
